MedPage Today's endocrinology roundup leads with the FDA's Class I recall of one lot of Vitruvias Therapeutics' 30-mg levothyroxine-liothyronine tablets. Class I is the agency's most serious recall classification.
Several GLP-1-related items appear in the roundup. A preprint suggests that a patient's weight trajectory before starting a GLP-1 drug may predict whether they become a 'super responder.' A study in Childhood Obesity found that nearly 17% of adolescents on a GLP-1 medication were diagnosed with at least one nutritional deficiency—most commonly vitamin D deficiency—within the first year. Eli Lilly reported that tirzepatide produced greater weight loss than semaglutide in an indirect comparison, while Novo Nordisk reported that doubling semaglutide's dose lowered major adverse cardiovascular event risk compared with switching to tirzepatide. Roche also halted development of emugrobart, a muscle-building drug intended for use with GLP-1/GIP agonists, after a disappointing phase II interim analysis.
Elsewhere, the American Diabetes Association and EASD issued updated joint consensus guidelines for managing type 1 diabetes in adults. The roundup also covers a phase IIb/III trial of remigromig for diabetic macular edema, a Berkeley healthy checkout ordinance study, and real-world data on salivary cortisone screening for adrenal insufficiency. These items are largely unrelated beyond their shared endocrinology focus.